ReviewJournal of nephropathology2013
Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney.
Review in Journal of nephropathology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02984111 (Placebo- Controlled,Randomized,Double Blind Trial of Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Placebo- Controlled,Randomized,Double Blind Trial of Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Drug Repositioning in Doxorubicin-Induced Cardiotoxicity Protection.International journal of molecular sciences · 2025Review
- Review
- Effects of insulin and metformin on fetal kidney development of streptozotocin-induced gestational diabetic albino rats.Anatomy & cell biology · 2019Article
- Erythropoietin Enhanced Recovery After Traumatic Nerve Injury: Myelination and Localized Effects.The Journal of hand surgery · 2016Article
- Erythropoietin Pretreatment Attenuates Seawater Aspiration-Induced Acute Lung Injury in Rats.Inflammation · 2016Article
- Gene therapy for radioprotection.Cancer gene therapy · 2015Review
- Protection of renal tubular cells by antioxidants: current knowledge and new trends.Cell journal · 2015Article
- Kidney tubular cell protection; recent findings.Iranian journal of pediatrics · 2014Article
- Metformin and diabetic kidney disease: a mini-review on recent findings.Iranian journal of pediatrics · 2014Review
- Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients.Cell journal · 2014Article
- Erythropoietin and renal protection.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2013Article
- Comment on: A model for prediction of cisplatin induced nephrotoxicity by kidney weight in experimental rats.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2013Article
- Comment on: Protective Role of Recombinant Human Erythropoietin in Kidney and Lung Injury Following Renal Bilateral Ischemia-reperfusion in Rat Model.International journal of preventive medicine · 2013Article
- Comment on: preventive effect of Teucrium polium on learning and memory deficits in diabetic rats.Medical science monitor basic research · 2013Article
- Renoprotective effects of metformin.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThere is a need to define the exact benefits and contraindications of use of high-dose recombinant human erythropoietin (EPO) for its non-hematopoietic function as a cytokine that enhances tissue repair after injury. This review compares the outcomes from use of EPO in the injured heart and kidney, two organs that are thought, traditionally, to have intrinsically-different repair mechanisms. EVIDENCE ACQUISITIONS: Directory of Open Access Journals (DOAJ), Google Scholar, Pubmed (NLM), LISTA (EBSCO) and Web of Science have been searched.
resultsOngoing work by us on EPO protection of ischemia-reperfusion-injured kidneys indicated, first, that EPO acutely enhanced kidney repair via anti-apoptotic, pro-regenerative mechanisms, and second, that EPO may promote chronic fibrosis in the long term. Work by others on the ischaemia-injured heart has also indicated that EPO promotes repair. Although myocardial infarcts are made up mostly of necrotic tissue, many publications state EPO is anti-apoptotic in the heart, as well as promoting healing via cell differentiation and stimulation of granulation tissue. In the case of the heart, promotion of fibrosis may be advantageous where an infarct has destroyed a zone of cardiomyocytes, but if EPO stimulates progressive fibrosis in the heart, this may promote cardiac failure.
conclusionsA major concern in relation to the use of EPO in a cytoprotective role is its stimulation of long-term inflammation and fibrosis. EPO usage for cytoprotection is undoubtedly advantageous, but it may need to be offset with an anti-inflammatory agent in some organs, like kidney and heart, where progression to chronic fibrosis after acute injury is often recorded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.